New Phase I trial investigates targeted molecular therapy to treat prostate cancer in US

US-based university hospital NewYork-Presbyterian and Weill Cornell Medicine have commenced a Phase I trial to evaluate a small molecule called Lutetium 177Lu-PSMA-617 for the treatment of patients with metastatic prostate cancer in the country.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news